203 related articles for article (PubMed ID: 21569999)
21. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
22. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
23. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
24. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].
Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284
[TBL] [Abstract][Full Text] [Related]
27. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
28. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
29. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
[TBL] [Abstract][Full Text] [Related]
32. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
33. Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer.
Chen X; Wu J; Lu H; Huang O; Shen K
Cancer Sci; 2012 Feb; 103(2):262-8. PubMed ID: 22035021
[TBL] [Abstract][Full Text] [Related]
34. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
[TBL] [Abstract][Full Text] [Related]
35. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
36. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
37. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
[TBL] [Abstract][Full Text] [Related]
38. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer.
Götte M; Kersting C; Ruggiero M; Tio J; Tulusan AH; Kiesel L; Wülfing P
Anticancer Res; 2006; 26(1B):621-7. PubMed ID: 16739330
[TBL] [Abstract][Full Text] [Related]
40. Immunomarker studies of fine-needle cytopuncture cell blocks for tumor response prediction after preoperative chemotherapy and prognosis in operable nonmetastatic primary breast carcinoma.
Becette V; Lerebours F; Spyratos F; Menet E; Tubiana-Hulin M; Briffod M
Breast J; 2011; 17(2):121-8. PubMed ID: 21306468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
